晶氨基胺类心肌病治疗:一个更新的评论
Dinusha Wanniarachchige1, Shazli Khan2, Stephen Pan1,3
1School of Medicine, New York Medical College, Valhalla, NY 10595, USA.
Journal of clinical medicine
|September 13, 2025
概括
新型疗法正在改变跨甲基氨酸心肌病 (ATTR-CM) 治疗的方法. 稳定剂和沉声器可以改善患者的结果,而基因编辑和抗体疗法对这种心力衰竭的原因显示出未来的希望.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 晶胺氨基酸心肌病变 (ATTR-CM) 是一种渐进式限制性心肌病变.
- ATTR-CM是由于错误折叠的跨胺蛋白沉积而产生的.
- 从历史上看,肝移植是主要的治疗选择.
研究的目的:
- 审查ATTR-CM目前和新兴的治疗策略.
- 调查ATTR-CM治疗的文献和临床试验.
- 探索ATTR-CM的个性化医疗方法.
主要方法:
- 现有研究的文献综述.
- 对正在进行的临床试验进行分析.
- 对新型治疗剂的评估.
主要成果:
- 晶氨酸 (TTR) 稳定剂 (塔法米迪斯,阿科拉米迪斯) 和TTR静音剂 (乌蒂西兰) 改善了生存,功能和生活质量.
- 在早期研究中,基因编辑和单克隆抗体疗法对粉样蛋白减少有希望.
- 目前的标准疗法包括稳定剂和沉声器.
结论:
- 新的疗法使ATTR-CM成为一种可管理的疾病.
- TTR稳定器和沉声器是有效的标准治疗方法.
- 基因编辑和单克隆抗体代表了ATTR-CM的未来有希望的治疗途径.
相关概念视频
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


